Potent and selective DNA-PK inhibitor (IC50 = 14 nM)
Selective for DNA-PK over a range of kinases including mTOR, PI 3-K, ATM and ATR
Potentiates the effects of doxorubicin (Cat
No
2252) and etoposide (Cat
No
1226) in vitro and etoposide in vivo
Also enhances CRISPR-Cas9-mediated homology-directed repair (HDR) efficiency 2 to 3-fold, and decreases nonhomologous end-joining (NHEJ) frequency ∽40%.